Cure My Disease

Don't miss your cure!

 Log in / Sign up

Exercise as medicine: can a 12-Week program shift breast cancer biomarkers?

NCT ID NCT07798492

Symptom relief Sponsor: Gazi University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 01, 2026 · Last updated Sep 02, 2026 · Updated 1 time

Summary

This trial tests whether a 12-week supervised aerobic exercise program can improve physical function, quality of life, and cognitive function in women who have finished treatment for early-stage breast cancer and are in remission. Researchers will measure blood levels of three biomarkers linked to inflammation and metabolism, along with walking distance and patient-reported outcomes, at the start, at week 6, and at week 12. The goal is to see if regular exercise is associated with beneficial changes in these measures.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A supervised aerobic exercise program
What this could lead to
If it works, this could point toward a simple, drug-free way to improve quality of life and physical function for breast cancer survivors, and possibly reduce inflammation-related biomarkers.
What could go wrong
This is a small, early-stage trial with only 20 participants, so results may not apply to all breast cancer survivors. Exercise is generally safe, but some participants may find it hard to stick with the program.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

20 people

The number who actually took part.

Started

Jun 2026

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria Women aged 18-65 years. Histologically confirmed stage I-II nonmetastatic breast cancer. Completion of indicated primary cancer treatment at least 6 months before enrollment and currently in remission. Ongoing endocrine therapy was permitted. No participation in regular structured physical activity during the preceding 6 months. Medically eligible to participate in aerobic exercise and study assessments. Physician clearance to participate in aerobic exercise. Residing in or near the city where the study was conducted. Provision of written informed consent. Exclusion Criteria Metastatic breast cancer. Clinically significant cardiovascular, respiratory, neurological, or musculoskeletal conditions that could limit safe participation in aerobic exercise. Clinically significant lymphedema. Pregnancy or breastfeeding. Use within the preceding 8 weeks of antidepressants, anxiolytics, antipsychotics, chronic analgesics, or sedatives considered likely to influence cognitive assessments or biological outcomes.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Aerobic exercise are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Aerobic exercise Breast cancer Breast cancer survivor

Contacts and locations

Locations

  • Ankara Yildirim Beyazit University

    Ankara, Turkey (Türkiye)

  • Gazi University

    Ankara, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.